CN109674795A - 伊曲康唑组合物和剂型及其使用方法 - Google Patents

伊曲康唑组合物和剂型及其使用方法 Download PDF

Info

Publication number
CN109674795A
CN109674795A CN201811419638.3A CN201811419638A CN109674795A CN 109674795 A CN109674795 A CN 109674795A CN 201811419638 A CN201811419638 A CN 201811419638A CN 109674795 A CN109674795 A CN 109674795A
Authority
CN
China
Prior art keywords
itraconazole
dosage
composition
lozanoc
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811419638.3A
Other languages
English (en)
Chinese (zh)
Inventor
斯图尔特·詹姆斯·马奇
大卫·海斯
斯特凡·鲁卡斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
Mayne Pharma International Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902624A external-priority patent/AU2012902624A0/en
Application filed by Mayne Pharma International Pty Ltd filed Critical Mayne Pharma International Pty Ltd
Publication of CN109674795A publication Critical patent/CN109674795A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201811419638.3A 2012-06-21 2013-06-21 伊曲康唑组合物和剂型及其使用方法 Pending CN109674795A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902624 2012-06-21
AU2012902624A AU2012902624A0 (en) 2012-06-21 Itraconazole formulations and uses
CN201380040270.9A CN104507480A (zh) 2012-06-21 2013-06-21 伊曲康唑组合物和剂型及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380040270.9A Division CN104507480A (zh) 2012-06-21 2013-06-21 伊曲康唑组合物和剂型及其使用方法

Publications (1)

Publication Number Publication Date
CN109674795A true CN109674795A (zh) 2019-04-26

Family

ID=49769445

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811419638.3A Pending CN109674795A (zh) 2012-06-21 2013-06-21 伊曲康唑组合物和剂型及其使用方法
CN201380040270.9A Pending CN104507480A (zh) 2012-06-21 2013-06-21 伊曲康唑组合物和剂型及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380040270.9A Pending CN104507480A (zh) 2012-06-21 2013-06-21 伊曲康唑组合物和剂型及其使用方法

Country Status (11)

Country Link
US (7) US8921374B2 (https=)
EP (1) EP2863911A4 (https=)
JP (2) JP2015531749A (https=)
KR (3) KR20200065093A (https=)
CN (2) CN109674795A (https=)
AU (3) AU2013278001A1 (https=)
BR (1) BR112014031706A8 (https=)
CA (1) CA2876909C (https=)
HK (1) HK1207288A1 (https=)
MX (1) MX366829B (https=)
WO (1) WO2013192566A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200065093A (ko) 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CA3073228A1 (en) 2017-08-20 2019-02-28 University Of Connecticut Azole analogues and methods of use thereof
US20190365743A1 (en) * 2018-05-30 2019-12-05 Hedgepath Pharmaceuticals, Inc. Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome
US12435067B2 (en) 2019-08-09 2025-10-07 University Of Connecticut Truncated itraconazole analogues and methods of use thereof
US20210346506A1 (en) 2020-05-07 2021-11-11 Guibai Liang Prodrug of itraconazole and uses thereof
WO2023007514A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy's Laboratories Limited Improved oral bioavailable pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260835A1 (en) * 1999-12-23 2008-10-23 F H Faulding & Co Limited Pharmaceutical compositions for poorly soluble drugs
CN101711156A (zh) * 2007-04-05 2010-05-19 约翰·霍普金斯大学 作为血管新生抑制剂的伊曲康唑的手性纯的异构物及羊毛甾醇14a-去甲基酶的抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3110794B2 (ja) 1991-06-05 2000-11-20 ユーシービージャパン株式会社 １，４−ジヒドロピリジン誘導体を含有する製剤
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
DE69628276T2 (de) 1995-07-26 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. Zubereitung von xanthinderivaten als feste dispersion
WO1997044014A1 (en) 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
ATE273002T1 (de) 1996-06-28 2004-08-15 Schering Corp Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
PT1039909E (pt) 1997-12-31 2003-02-28 Choongwae Pharma Corp Metodo de producao e composicao de uma preparacao oral de itraconazole
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
WO2000040220A1 (en) 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
KR100529766B1 (ko) 2003-09-09 2005-11-17 한미약품 주식회사 음식물 섭취에 따른 영향이 적은, 이트라코나졸경구투여용 조성물 및 이의 제조 방법
US20050058670A1 (en) 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
JP5538718B2 (ja) * 2005-08-08 2014-07-02 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつイトラコナゾール組成物
BRPI0713533A2 (pt) * 2006-06-26 2012-04-17 Mutual Pharmaceutical Co formulações de agente ativo, métodos de fabricação, e métodos de uso
KR20200065093A (ko) 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260835A1 (en) * 1999-12-23 2008-10-23 F H Faulding & Co Limited Pharmaceutical compositions for poorly soluble drugs
CN101711156A (zh) * 2007-04-05 2010-05-19 约翰·霍普金斯大学 作为血管新生抑制剂的伊曲康唑的手性纯的异构物及羊毛甾醇14a-去甲基酶的抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
叶惠雅等: "伊曲康唑治疗甲癣的疗效观察 ", 《基层医学论坛》 *

Also Published As

Publication number Publication date
US20150099763A1 (en) 2015-04-09
US11638758B2 (en) 2023-05-02
WO2013192566A1 (en) 2013-12-27
US20190125879A1 (en) 2019-05-02
JP2018162304A (ja) 2018-10-18
US10463740B2 (en) 2019-11-05
CA2876909A1 (en) 2013-12-27
HK1207288A1 (en) 2016-01-29
AU2018201298B2 (en) 2020-05-14
KR20210043721A (ko) 2021-04-21
MX2015000179A (es) 2016-02-16
US20200138959A1 (en) 2020-05-07
US9272046B2 (en) 2016-03-01
JP2015531749A (ja) 2015-11-05
AU2018201298A1 (en) 2018-03-15
AU2013278001A1 (en) 2015-01-22
US10806792B2 (en) 2020-10-20
CN104507480A (zh) 2015-04-08
MX366829B (es) 2019-07-25
EP2863911A4 (en) 2016-07-13
US20160030582A1 (en) 2016-02-04
KR20200065093A (ko) 2020-06-08
BR112014031706A2 (pt) 2017-06-27
US20210038728A1 (en) 2021-02-11
AU2020217438A1 (en) 2020-09-03
EP2863911A1 (en) 2015-04-29
US8921374B2 (en) 2014-12-30
BR112014031706A8 (pt) 2021-10-19
KR20150043296A (ko) 2015-04-22
US20170348421A1 (en) 2017-12-07
JP6757367B2 (ja) 2020-09-16
CA2876909C (en) 2022-08-16
US9713642B2 (en) 2017-07-25
US20140005205A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
CN109674795A (zh) 伊曲康唑组合物和剂型及其使用方法
Rapalli et al. Application of QbD principles in nanocarrier-based drug delivery systems
Gupta et al. Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate
JP5449784B2 (ja) 抗癌用途のためのドキソルビシン製剤
JP2009538918A (ja) フェニレフリンを含有する徐放薬学的投薬形態
EP2374450B1 (en) Flupentixol compositions
Sakr et al. Pharmacokinetics of buspirone extended‐release tablets: a single‐dose study
Nayak et al. Comparative in vitro bioequivalence analysis of some ciprofloxacin HCl generic tablets
Al-Shadeedi et al. Formulation and evaluation of carbimazole orodispersible tablet
Israr et al. Pharmaceutical evaluation of cefuroxime axetil tablets available in drug market of Pakistan
CN103768068B (zh) 一种波生坦药物组合物
TW200811123A (en) Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
US11801252B2 (en) Pharmaceutical composition
Al-Kubati et al. Comparison of in vitro dissolution of Bisoprolol Fumarate tablets of five Brands marketed in Aden, Yemen
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
KR101798184B1 (ko) 약물 방출제어용 조성물
Marroum et al. In vivo Bioavailability/Bioequivalence Waivers
Islam Determination of the Release Kinetics of Drug from Six Brands of Levoceterezine dihydrochloride (Alcet, Clarigen, Seasonix, Purotrol, Lecet, lozin) Available in Bangladesh
Yarsan et al. Influence of mercury chloride-renal failure on pharmacokinetics of sulphamethoxazole after oral administration in mice

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190426

WD01 Invention patent application deemed withdrawn after publication